| Literature DB >> 34794476 |
Jozo Grgic1, Ivana Grgic2, Juan Del Coso3, Brad J Schoenfeld4, Zeljko Pedisic5.
Abstract
BACKGROUND: We aimed to perform an umbrella review of meta-analyses examining the effects of sodium bicarbonate supplementation on exercise performance.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34794476 PMCID: PMC8600864 DOI: 10.1186/s12970-021-00469-7
Source DB: PubMed Journal: J Int Soc Sports Nutr ISSN: 1550-2783 Impact factor: 5.150
Fig. 1Flow-chart presenting the search process
Summary of the meta-analyses included in the umbrella review
| Reference | Included studies | Number of included primary studies (sample size) | Performance test/outcome | Effect size and | |
|---|---|---|---|---|---|
| Christensen et al. [ | Crossover study designs | 25 studies ( | Endurance events lasting ∼45 s to 8 min | 0.40 (95% CI: 0.27, 0.54); | n/a |
| Grgic [ | Crossover study designs | 10 studies ( | Mean and peak power in single and repeated Wingate tests | Peak power bout 1: − 0.01 (95% CI: − 0.06, 0.04); Peak power bout 2: 0.02 (95% CI: − 0.10, 0.13); Peak power bout 3: 0.09 (95% CI: 0.00, 0.17); Peak power bout 4: 0.29 (95% CI: − 0.13, 0.71); Mean power bout 1: 0.02 (95% CI: − 0.07, 0.11); Mean power bout 2: 0.09 (95% CI: 0.03, 0.16); Mean power bout 3: 0.21 (95% CI: − 0.16, 0.58); Mean power bout 4: 0.62 (95% CI: 0.15, 1.08); | Peak power bout 1: 0% Peak power bout 2: 7% Peak power bout 3: 0% Peak power bout 4: 0% Mean power bout 1: 0% Mean power bout 2: 0% Mean power bout 3: 0% Mean power bout 4: 0% |
| Grgic et al. [ | Crossover study designs | 5 studies ( | Yo-Yo test performance | 0.36 (95% CI: 0.10, 0.63); | 14% |
| Grgic et al. [ | Crossover study designs | 13 studies for muscle endurance ( | Muscle endurance and muscle strength | Muscle endurance: 0.37 (95% CI: 0.15, 0.59); Muscle strength: − 0.03 (95% CI: − 0.18, 0.12); | Muscle endurance: 70% Muscle strength: 45% |
| Lopes-Silva et al. [ | Crossover study designs | 6 studies ( | Measures of repeated-sprint ability (total work, best sprint, and last sprint performance) | Total work: 0.43 (95% CI: −0.11, 0.97); Best sprint: 0.02 (95% CI: − 0.30, 0.34); Last sprint: 0.20 (95% CI: − 0.13, 0.52); | Total work: 0% Best sprint: 0% Last sprint: 69% |
| Lopes-Silva et al. [ | Crossover and between-group study designs | 6 studies ( | Mean and peak power in single and repeated Wingate tests | Peak power: 0.02 (95% CI: − 0.19, 0.23); Mean power: 0.15 (95% CI: − 0.06, 0.36); Peak power: 1.21 (95% CI: 0.83, 1.42); Mean power: 1.26 (95% CI: 0.96, 1.56); | Peak power: 0% Mean power: 0% Peak power: 27% Mean power: 88% |
| Carr et al. [ | Crossover study designs | 26 studies ( | General mean power | 1.7% (90% CL: 90% CL: − 0.3%, 3.7) | n/a |
| Turnes et al. [ | Crossover study designs | 5 studies ( | Mean power in 2000-m rowing | 1.4% (90% CL: 0.1, 2.6%) | n/a |
CI: confidence interval; CL: confidence limit; a12 studies were included in the meta-analysis
Result of the quality assessment using the Assessing the Methodological Quality of Systematic Reviews 2 (AMSTAR 2) checklist
| Reference | AMSTAR 2 items | Score | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | ||
| Carr et al. [ | Yes | No | Yes | Yes | Yes | Yes | No | Yes | No | No | Yes | n/a | n/a | Yes | Yes | Yes | 63% MQ |
| Christensen et al. [ | Yes | No | Yes | Yes | Yes | Unclear | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | 75% MQ |
| Grgic [ | Yes | No | Yes | Yes | No | No | No | Yes | Yes | No | Yes | Yes | Yes | Yes | Yes | Yes | 69% MQ |
| Grgic et al. [ | Yes | No | Yes | Yes | Yes | Yes | No | Yes | Yes | No | Yes | Yes | Yes | Yes | Yes | Yes | 81% HQ |
| Grgic et al. [ | Yes | No | Yes | Yes | Yes | Yes | No | Yes | Yes | No | Yes | Yes | Yes | Yes | Yes | Yes | 81% HQ |
| Lopes-Silva et al. [ | Yes | No | Yes | Yes | Yes | Unclear | No | Yes | Yes | No | Yes | Yes | Yes | Yes | Yes | Yes | 75% MQ |
| Lopes-Silva et al. [ | Yes | No | Yes | Yes | Yes | Unclear | No | Yes | Yes | No | Yes | Yes | Yes | Yes | No | Yes | 69% MQ |
| Turnes et al. [ | Yes | No | Yes | Yes | Unclear | Unclear | No | Yes | No | No | Yes | n/a | n/a | Yes | Yes | Yes | 50% MQ |
MQ: moderate quality; HQ: high quality
Results of the quality of evidence assessment using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) criteria
| Reference | GRADE items | Quality of the evidence* | ||||
|---|---|---|---|---|---|---|
| Risk of bias | Inconsistency | Indirectness | Imprecision | Publication bias | ||
| Carr et al. [ | Unclear (no quality assessment performed) | Not serious | Serious indirectness (only 15% of participants included in the analysis were women) | Not serious | Undetected | Low ⊕ ⊕ ΟΟ |
| Christensen et al. [ | Not serious | Not serious | Serious indirectness (only 9% of participants included in the analysis were women) | Not serious | Strongly suspected (no “grey” literature searches; asymmetry of the funnel plot was not explored; the effect size of the largest study was smaller than the pooled estimate) | Low ⊕ ⊕ ΟΟ |
| Grgic [ | Peak power: not serious | Peak power: not serious | Peak power: serious indirectness (none of the participants included in the analysis were women) | Peak power: not serious | Peak power: undetected | Peak power: moderate ⊕ ⊕ ⊕Ο |
| Mean power: not serious | Mean power: not serious | Mean power: serious indirectness (only 15% of participants included in the analysis were women) | Mean power: not serious | Mean power: undetected | Mean power: moderate ⊕ ⊕ ⊕Ο | |
| Grgic et al. [ | Not serious | Not serious | Serious indirectness (none of the participants included in the analysis were women) | Not serious | Undetected | Moderate ⊕ ⊕ ⊕Ο |
| Grgic et al. [ | Muscle endurance: not serious | Not serious | Serious indirectness (only 5% of participants included in the analysis were women) | Not serious | Strongly suspected (“grey” literature searches were performed; however, asymmetry of the funnel plot was not explored and the effect size of the largest study was smaller than the pooled estimate) | Low ⊕ ⊕ ΟΟ |
| Muscle strength: not serious | Not serious | Serious indirectness (only 4% of participants included in the analysis were women) | Not serious | Undetected | Moderate ⊕ ⊕ ⊕Ο | |
| Lopes-Silva et al. [ | Total work: not serious | Total work: not serious | Total work: serious indirectness (only 28% of participants included in the analysis were women) | Total work: serious limitation | Total work: undetected | Low ⊕ ⊕ ΟΟ |
| Best sprint: not serious | Best sprint: not serious | Best sprint: serious indirectness (only 23% of participants included in the analysis were women) | Best sprint: not serious | Best sprint: undetected | Moderate ⊕ ⊕ ⊕Ο | |
| Last sprint: not serious | Last sprint: not serious | Last sprint: serious indirectness (only 23% of participants included in the analysis were women) | Last sprint: not serious | Last sprint: undetected | Moderate ⊕ ⊕ ⊕Ο | |
| Lopes-Silva et al. [ | Acute ingestion, peak power: not serious | Acute ingestion, peak power: not serious | Acute ingestion, peak power: serious indirectness (none of the participants included in the analysis were women) | Acute ingestion, peak power: not serious | Acute ingestion, peak power: strongly suspected (no “grey” literature searches; asymmetry of the funnel plot was not explored; the effect size of the largest study was similar to the pooled estimate) | Low ⊕ ⊕ ΟΟ |
| Acute ingestion, mean power: not serious | Acute ingestion, mean power: not serious | Acute ingestion, mean power: serious indirectness (none of the participants included in the analysis were women) | Acute ingestion, mean power: not serious | Acute ingestion, mean power: strongly suspected (no “grey” literature searches; asymmetry of the funnel plot was not explored; the effect size of the largest study was similar to the pooled estimate) | Low ⊕ ⊕ ΟΟ | |
| Multi-day ingestion, peak power: not serious | Multi-day ingestion, peak power: not serious | Multi-day ingestion, peak power: serious indirectness (none of the participants included in the analysis were women) | Multi-day ingestion, peak power: not serious | Multi-day ingestion, peak power: strongly suspected (no “grey” literature searches; asymmetry of the funnel plot was not explored; the effect size of the largest study was similar to the pooled estimate) | Low ⊕ ⊕ ΟΟ | |
| Multi-day ingestion, mean power: not serious | Multi-day ingestion, mean power: not serious | Multi-day ingestion, mean power: serious indirectness (none of the participants included in the analysis were women) | Multi-day ingestion, mean power: not serious | Multi-day ingestion, mean power: strongly suspected (no “grey” literature searches; asymmetry of the funnel plot was not explored; the effect size of the largest study was similar to the pooled estimate) | Low ⊕ ⊕ ΟΟ | |
| Turnes et al. [ | Unclear (no quality assessment performed) | Not serious | Serious indirectness (only 10% of participants included in the analysis were women) | Not serious | Undetected | Low ⊕ ⊕ ΟΟ |
Studies were classified as: ⊕ ⊕ ⊕ ⊕ = high quality; ⊕ ⊕ ⊕Ο = moderate quality; ⊕ ⊕ ΟΟ = low quality; ⊕ΟΟΟ = very low quality
Fig. 2Summary of pooled effect sizes (ES) and 95% confidence intervals (CI) from the meta-analyses that used Cohen’s d for data analysis. AI: acute ingestion of sodium bicarbonate; BS: best sprint; LS: last sprint; MDI: multi-day ingestion of sodium bicarbonate; RSA: repeated-sprint ability; TW: total work
Effects of sodium bicarbonate supplementation on exercise performance: summary findings, methodological quality of literature reviews, and quality of evidence
| Quality of evidence | Methodological quality of literature reviews | |
|---|---|---|
| Moderate | High | |
| Low | • Endurance events lasting ∼45 s to 8 min in Christensen et al. [ • Anaerobic power in the Wingate test using the multiple-day supplementation protocol in Lopes-Silva et al. [ • 2000-m rowing in Turnes et al. [ | • Muscle endurance in Grgic et al. [ |
| Moderate | • Anaerobic power in the repeated-bout Wingate test in Grgic [ | • Yo-Yo test performance in Grgic et al. [ |
| Low | • General mean power in Carr et al. [ • Repeated-sprint ability (total work) in Lopes-Silva et al. [ • Anaerobic power in the Wingate test using single-dose supplementation protocol in Lopes-Silva et al. [ | / |
| Moderate | • Repeated-sprint ability (best sprint) in Lopes-Silva et al. [ • Repeated-sprint ability (last sprint) in Lopes-Silva et al. [ | • Muscle strength in Grgic et al. [ |
Note: Quality of evidence was evaluated using the GRADE criteria; methodological quality of the review was evaluated using the AMSTAR 2 checklist
Fig. 3Summary of pooled percent changes and 90% confidence limits (CL) from the meta-analyses that used percent changes for data analysis
Findings of subgroup analyses reported in the included reviews
| Reference | Subgroup analyses focus | Subgroups analyses results |
|---|---|---|
| Carr et al. [ | Increase in dose by 1 mmoL/kg/body mass | 0.5% (90% CL: −0.1, 0.6%) |
| Five extra bouts | 0.6% (90% CL: 0.2, 1.0%) | |
| 10 × duration | − 0.6% (90% CL: − 1.2, 0.3%) | |
| Non-athletes | −1.1% (90% CL: − 2.2, 0.0%) | |
| Females | −0.7% (90% CL: − 2.1, 0.7%) | |
| Non-blinded | 0.2% (90% CL: −0.5, 0.9%) | |
| Grgic et al. [ | Large muscle groups | ES: 0.40 (95% CI: 0.13, 0.66) |
| Small muscle groups | ES: 0.31 (95% CI: 0.04, 0.59) | |
| One time point of ingestion | ES: 0.53 (95% CI: 0.14, 0.93) | |
| Multiple time points of ingestion | ES: 0.23 (95% CI: 0.05, 0.42) | |
| Grgic et al. [ | Tested in a rested state | ES: 0.02 (95% CI: − 0.09, 0.13) |
| Tested in a fatigued state | ES: −0.16 (95% CI: − 0.59, 0.28) | |
| One time point of ingestion | ES: −0.14 (95% CI: − 0.50, 0.21) | |
| Multiple time points of ingestion | ES: 0.04 (95% CI: −0.06, 0.14) | |
| Lopes-Silva et al. [ | Acute ingestion: Wingate bout 1 | ES: − 0.07 (95% CI: − 0.36, 0.23) |
| Acute ingestion: Wingate bout 2 | ES: 0.00 (95% CI: − 0.42, 0.42) | |
| Acute ingestion: Wingate bout 3 | ES: 0.14 (95% CI: −0.28, 0.56) | |
| Multi-day ingestion: Wingate bout 1 | ES: 0.79 (95% CI: 0.20, 1.37) | |
| Multi-day ingestion: Wingate bout 2 | ES: 1.52 (95% CI: 0.90, 2.13) | |
| Multi-day ingestion: Wingate bout 3 | ES: 0.89 (95% CI: 0.33, 1.45) | |
| Multi-day ingestion: Wingate bout 4 | ES: 1.36 (95% CI: 0.76, 1.96) | |
| Lopes-Silva et al. [ | Acute ingestion: Wingate bout 1 | ES: 0.12 (95% CI: −0.18, 0.41) |
| Acute ingestion: Wingate bout 2 | ES: 0.14 (95% CI: −0.28, 0.56) | |
| Acute ingestion: Wingate bout 3 | ES: 0.22 (95% CI: −0.20, 0.65) | |
| Multi-day ingestion: Wingate bout 1 | ES: 0.91 (95% CI: 0.43, 1.39) | |
| Multi-day ingestion: Wingate bout 2 | ES: 1.04 (95% CI: 0.46, 1.62) | |
| Multi-day ingestion: Wingate bout 3 | ES: 1.66 (95% CI: 0.95, 2.38) | |
| Multi-day ingestion: Wingate bout 4 | ES: 2.09 (95% CI: 1.31, 2.87) |
ES: effect size; CL: confidence limit; CI: confidence interval